L-carnitine in a certain concentration increases expression of cell surface marker CD34 and apoptosis in the rat bone marrow CD34+ hematopoietic stem cells

Document Type : Full paper (Original article)


1 Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran

2 Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

3 Department of Anatomical Sciences, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran


Background: Stem cell based therapy has been encouraged as an attractive method in regenerative medicine. Poor survival and maintenance of the cells transferred into the damaged tissue are broadly accepted as serious barriers to enhancing the efficacy of regenerative medicine. For this reason, some antioxidants such as L-carnitine (LC) are used as a favorite strategy to improve cell survival and retention properties. Aims: This study aims to evaluate the effect of LC on the expression of CD34 marker and its effect on apoptosis and SUZ12 gene expression. Methods: Rat bone marrow mono-nuclear cells (rBMNCs) were isolated. Then, CD34+ hematopoietic stem cells (HSCs) were enriched using the magnetic activated cell sorting (MACS) method. The cells were treated with 0.2 and 0.4 mM LC. Gene and protein expression levels of the CD34 were then measured by real-time PCR and flow cytometry, respectively. The percentage of apoptosis and SUZ12 gene expression were measured using the Annexin V/PI method and real-time PCR, respectively. Results: The results showed that in the experimental group, of the CD34+ HSCs treated with 0.2 mM LC, gene and protein expressions of CD34 increased by 1.7 fold and 0.49%, respectively. At the concentration of 0.4 mM, the early cell apoptosis increased by 25.9% (P<0.05). Also, in the concentration of 0.2 and 0.4 mM LC, the SUZ12 gene expression increased by 1.10 and 1.75 folds compared to the control group (P<0.05 and P<0.01), respectively. Conclusion: The results of this study could be used to improve chronic myeloid leukemia (CML) as a multidirectional therapeutic strategy.


Main Subjects

Adibkia, K; Ehsani, A; Jodaei, A; Fathi, E; Farahzadi, R and Barzegar-Jalali, M (2021). Silver nanoparticles induce the cardiomyogenic differentiation of bone marrow derived mesenchymal stem cells via telomere length extension. Beilstein. J. Nanotechnol., 12: 786-797.
Attar, A (2014). Changes in the cell surface markers during normal hematopoiesis: a guide to cell isolation. G. J. Hematol. Blood. Trans., 1: 20-28.
Baylin, SB and Ohm, JE (2006). Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer. 6: 107-116.
Bracken, AP; Pasini, D; Capra, M; Prosperini, E; Colli, E and Helin, K (2003). EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO. J., 22: 5323-5335.
Civin, C (1984). A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-Ia cells. J. Immunol., 133: 157-165.
de Fabritiis, P; Dowding, C; Bungey, J; Chase, A; Angus, G; Szydlo, R and Goldman, JM (1993). Phenotypic characterization of normal and CML CD34-positive cells: only the most primitive CML progenitors include Ph-neg cells. Leuk. Lymphoma., 11: 51-61.
Druker, BJ; Guilhot, F; O’Brien, SG; Gathmann, I; Kantarjian, H; Gattermann, N; Deininger, MW; Silver, RT; Goldman, JM; Stone, RM; Cervantes, F and Hochhaus, A (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med., 355: 2408-2417.
Durazzo, A; Lucarini, M; Nazhand, A; Souto, SB; Silva, AM; Severino, P; Souto, EB and Santini, A (2020). The nutraceutical value of carnitine and its use in dietary supplements. Molecules. 25: 2127-2148.
Fan, JP; Kim, HS and Han, GD (2009). Induction of apoptosis by L-carnitine through regulation of two main pathways in Hepa1c1c 7 cells. Amino Acids. 36: 365-372.
Farahzadi, R; Mesbah-Namin, SA; Zarghami, N and Fathi, E (2016). L-carnitine effectively induces hTERT gene expression of human adipose tissue-derived mesenchymal stem cells obtained from the aged subjects. Int. J. Stem. Cells., 9: 107-114.
Fathi, E; Farahzadi, R; Javanmardi, S and Vietor, I (2020a). L-carnitine extends the telomere length of the cardiac differentiated CD117+-expressing stem cells. Tissue Cell. 67: 1-9.
Fathi, E; Farahzadi, R and Valipour, B (2021). Alginate/gelatin encapsulation promotes NK cells differentiation potential of bone marrow resident C-kit+ hematopoietic stem cells. Int. J. Biol. Macromol., 177: 317-327.
Fathi, E; Farahzadi, R; Vietor, I and Javanmardi, S (2020b). Cardiac differentiation of bone-marrow-resident c-kit+ stem cells by L-carnitine increases through secretion of VEGF, IL6, IGF-1, and TGF-β as clinical agents in cardiac regeneration. J. Biosci., 45: 1-11.
Fathi, E; Sanaat, Z and Farahzadi, R (2019). Mesenchymal stem cells in acute myeloid leukemia: a focus on mechanisms involved and therapeutic concepts. Blood Res., 54: 165-174.
Fathi, E; Valipour, B and Farahzadi, R (2020c). Targeting the proliferation inhibition of chronic myeloid leukemia cells by bone marrow derived-mesenchymal stem cells via ERK pathway as a therapeutic strategy. Acta Med. Iran., 58: 199-206.
Fathi, E and Vietor, I (2021). Mesenchymal stem cells promote caspase expression in Molt-4 leukemia cells via GSK-3α/and ERK1/2 signaling pathways as a therapeutic strategy. Curr. Gene. Ther., 21: 81-88.
Fouqué, A and Legembre, P (2015). The CD95/CD95L signaling pathway: a role in carcinogenesis. Cancer Immunol., 1846: 143-160.
Gambelli, F; Sasdelli, F; Manini, I; Gambarana, C; Oliveri, G; Miracco, C and Sorrentino, V (2012). Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression. Cell. Biol. Int., 36: 29-38.
Genovese, P; Schiroli, G; Escobar, G; Di Tomaso, T; Firrito, C; Calabria, A; Moi, D; Mazzieri, R; Bonini, C; Holmes, MC; Gregory, PD; Burg, M; Genter, B; Montini, E; Lombardo, A and Naldini, L (2014). Targeted genome editing in human repopulating haematopoietic stem cells. Nature. 510: 235-240.
Ghose, P and Shaham, S (2020). Cell death in animal development. Development. 147: 1-12.
Heidari, HR; Fathi, E; Montazersaheb, S; Mamandi, A; Farahzadi, R; Zalavi, S and Nozad Charoudeh, H (2021). Mesenchymal stem cells cause telomere length reduction of Molt-4 cells via caspase-3, BAD and P53 apoptotic athway. Int. J. Mol. Cell. Med., 10: 113-122.
Kanno, R; Janakiraman, H and Kanno, M (2008). THIS ARTICLE HAS BEEN RETRACTED Epigenetic regulator polycomb group protein complexes control cell fate and cancer. Cancer Sci., 99: 1077-1084.
Kesavardhana, S; Malireddi, RS and Kanneganti, TD (2020). Caspases in cell death, inflammation, and pyroptosis. Annu. Rev. Immunol., 38: 567-595.
Kouttab, NM and De Simone, C (1993). Modulation of cytokine production by carnitine. Mediators. Inflamm., 2: 25-28.
Lee, SC; Miller, S; Hyland, C; Kauppi, M; Lebois, M; Di Rago, L; Metcalf, D; Kinkel, SA; Josefsson, EC; Blewitt, ME; Majewski, IJ and Alexander, WS (2015). Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis. Blood. 126: 167-175.
Levoin, N; Jean, M and Legembre, P (2020). CD95 structure, aggregation and cell signaling. Front. Cell. Dev. Biol., 8: 1-13.
Lin, HD; Fong, CY; Biswas, A and Bongso, A (2020). Allogeneic human umbilical cord Wharton’s jelly stem cells increase several-fold the expansion of human cord blood CD34+ cells both in vitro and in vivo. Stem. Cell. Res. Ther., 11: 1-18.
Lu, Y; Chan, YT; Tan, HY; Li, S; Wang, N and Feng, Y (2020). Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol. Cancer. 19: 1-16.
Malaguarnera, M; Risino, C; Gargante, MP; Oreste, G; Barone, G; Tomasello, AV; Costanzo, M and Cannizzaro, MA (2006). Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World J. Gastroenterol., 12: 4541-4545.
Metcalf, D (2008). Hematopoietic cytokines. Blood. 111: 485-491.
Mobarak, H; Fathi, E; Farahzadi, R; Zarghami, N and Javanmardi, S (2017). L-carnitine significantly decreased aging of rat adipose tissue-derived mesenchymal stem cells. Vet. Res. Commun., 41: 41-47.
Montazersaheb, S; Avci, ÇB; Bagca, BG; Ay, NPO; Tarhriz, V; Nielsen, PE; Charoudeh, HN and Hejazi, MS (2020). Targeting TdT gene expression in Molt-4 cells by PNA-octaarginine conjugates. Int. J. Biol. Macromol., 164: 4583-4590.
Montazersaheb, S; Fathi, E and Farahzadi, R (2021). Cytokines and signaling pathways involved in differentiation potential of hematopoietic stem cells towards natural killer cells. Tissue Cell. 70: 1-8.
Montazersaheb, S; Kazemi, M; Nabat, E; Nielsen, PE and Hejazi, MS (2019). Downregulation of TdT expression through splicing modulation by antisense peptide nucleic acid (PNA). Curr. Pharm. Biotechnol., 20: 168-178.
Mutomba, MC; Yuan, H; Konyavko, M; Adachi, S; Yokoyama, CB; Esser, V; McGarry, JD; Babior, BM and Gottlieb, RA (2000). Regulation of the activity of caspases by L-carnitine and palmitoylcarnitine. FEBS. Lett., 28: 19-25.
Nielsen, JS and McNagny, KM (2009). CD34 is a key regulator of hematopoietic stem cell trafficking to bone marrow and mast cell progenitor trafficking in the periphery. Microcircirculation. 16: 487-496.
Obeng, E (2021). Apoptosis (programmed cell death) and its signals-A review. Braz. J. Biol., 81: 1133-1143.
Pasini, D; Bracken, AP; Hansen, JB; Capillo, M and Helin, K (2007). The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol. Cell. Biol., 27: 3769-3779.
Penfornis, P; Fernandes, JD and Pochampally, RR (2018). Polycomb group protein Suz12 is regulated by a novel miRNA-like small RNA. Sci. Rep., 8: 1-14.
Pizzatti, L; Binato, R; Cofre, J; Gomes, BE; Dobbin, J; Haussmann, ME; D’Azambuja, D; Bouzas, LF and Abdelhay, E (2010). SUZ12 is a candidate target of the non-canonical WNT pathway in the progression of chronic myeloid leukemia. Genes Chromosomes Cancer. 49: 107-118.
Scherberich, A; Di Di Maggio, N and McNagny, KM (2013). A familiar stranger: CD34 expression and putative functions in SVF cells of adipose tissue. World J. Stem. Cells. 5: 1-8.
Thomas, N and Zachariah, SM (2013). Pharmacological activities of chromene derivatives: an overview. Asian J. Pharm. Clin. Res., 6: 11-15.
Tie, R; Li, H; Cai, S; Liang, Z; Shan, W; Wang, B; Tan, Y; Zheng, W and Huang, H (2019). Interleukin-6 signaling regulates hematopoietic stem cell emergence. Exp. Mol. Med., 51: 1-12.
Vardiyan, R; Ezati, D; Anvari, M; Ghasemi, N and Talebi, A (2020). Effect of L-carnitine on the expression of the apoptotic genes Bcl-2 and Bax. Clin. Exp. Reprod. Med., 47: 155-160.
Vescovo, G; Ravara, B; Gobbo, V; Sandri, M; Angelini, A; Della Barbera, M; Dona, M; Peluso, G; Calvani, M; Mosconi, L and Libera, LD (2002). L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. Am. J. Physiol. Cell. Physiol., 283: C802-C810.
Walz, C and Sattler, M (2006). Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid
leukemia (CML). Crit. Rev. Oncol. Hematol., 57: 145-164.
Wang, L; Liu, Y; Li, W; Jiang, X; Ji, Y; Wu, X; Xu, L; Qiu, Y; Zhao, K; Wei, T; Li, Y; Zhao, Y and Chen, C (2011). Selective targeting of gold nanorods at the mitochondria of cancer cells: implications for cancer therapy. Nano. Lett., 11: 772-780.
Wu, YN; Yang, LX; Shi, XY; Li, IC; Biazik, JM; Ratinac, KR; Chen, DH; Thordarson, P; Shieh, DB and Braet, F (2011). The selective growth inhibition of oral cancer by iron core-gold shell nanoparticles through mitochondria-mediated autophagy. Biomaterials. 32: 4565-4573.
Yang, L; Shi, P; Zhao, G; Xu, J; Peng, W; Zhang, J; Zhang, G; Wang, X; Dong, Z; Chen, F and Cui, H (2020). Targeting cancer stem cell pathways for cancer therapy. Signal Transduct. Target. Ther., 5: 1-35.
Yazdanpanah, M; Luo, X; Lau, R; Greenberg, M; Fisher, LJ and Lehotay, DC (1997). Cytotoxic aldehydes as possible markers for childhood cancer. Free. Radic. Biol. Med., 23: 870-878.
Zoghbi, HY and Beaudet, AL (2016). Epigenetics and human disease. Cold. Spring Harb. Perspect. Biol., 8: 1-28.